Evommune (EVMN) Corporate presentation summary

Addressing chronic inflammation and unmet medical needs

• Chronic inflammation contributes to 3 out of 5 deaths globally and costs at least $90B annually.

• Current therapies for chronic inflammation have significant efficacy and safety limitations.

• Focus on immune-mediated diseases with critical gaps in care and high unmet need.

Pipeline overview and clinical programs

• Two lead programs in Phase 2: EVO756 (oral MRGPRX2 antagonist) and EVO301 (IL-18BP fusion protein).

• EVO756 targets mast cell-mediated diseases and neuroinflammation, with trials in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD).

• EVO301 is a long-acting injectable designed to neutralize IL-18 signaling, with trials in AD and plans for ulcerative colitis.

• Three Phase 2 readouts expected in 2026 across both programs.

Clinical data and trial results

• EVO756 demonstrated robust clinical activity and was well-tolerated in Phase 1 and 2 trials, with up to 30% complete response at 4 weeks in CIndU.

• Dose response modeling supports both QD and BID dosing regimens for EVO756.

• Safety profile for EVO756 showed no serious adverse events or discontinuations due to adverse events.

• EVO301 targets a clinically validated pathway (IL-18) implicated in multiple inflammatory and autoimmune diseases.